Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study

INTRODUCTION: Given the ageing epidemic of tuberculosis (TB), China is facing an unprecedented opportunity provided by the first clinically approved next-generation TB vaccine Vaccae, which demonstrated 54.7% efficacy for preventing reactivation from latent infection in a phase III trial. We aim to...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Jun-Jie, Zang, Xiao, Yue, Wan-Lu, Zhai, Pei-Yao, Zhang, Qiong, Li, Chun-Hu, Zhuang, Xun, Liu, Min, Qin, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254880/
https://www.ncbi.nlm.nih.gov/pubmed/37257938
http://dx.doi.org/10.1136/bmjgh-2023-012306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10254880/
https://www.ncbi.nlm.nih.gov/pubmed/37257938
http://dx.doi.org/10.1136/bmjgh-2023-012306

Ejemplares similares